In addition, our study supported with previous publication that PRMT5 could be a novel marker for pancreatic cancer patients’ classification and potential therapeutic target, providing preclinical evidence that PRMT5 could be translated into a therapeutic target for treatment for pancreatic cancer. This evidence concerns the gene PRMT5 and pancreatic neoplasm.